{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:54:07Z","timestamp":1793883247914,"version":"4.7.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2025QC1699"],"award-info":[{"award-number":["ZR2025QC1699"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82570247"],"award-info":[{"award-number":["No.82570247"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Taishan Scholars Program of Shandong Province","award":["No.tstp20250756"],"award-info":[{"award-number":["No.tstp20250756"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"DOI":"10.1186\/s40364-026-00938-8","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:05:47Z","timestamp":1779447947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["In vivo CAR-T therapy: latest updates from the 2025 ASH annual meeting"],"prefix":"10.1186","volume":"14","author":[{"given":"Shule","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangcai","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangxiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"938_CR1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/ajh.70201","volume":"101","author":"C Filippatos","year":"2026","unstructured":"Filippatos C, Kanteli I, Pasipoularidou DG, Gavriatopoulou M, Tentolouris A, Malandrakis P, et al. Chimeric Antigen Receptor T-Cells (CAR T\u2010Cells) in Hematological Malignancies: A Systematic Review and Meta\u2010Analysis of Proportions From Clinical Trials. Am J Hematol. 2026;101:497\u2013511.","journal-title":"Am J Hematol"},{"key":"938_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-025-01759-2","volume":"18","author":"J Xu","year":"2025","unstructured":"Xu J, Chen Z, Su L, Ren A, Mei H. In vivo CAR cell therapy: from bench to bedside. J Hematol OncolJ Hematol Oncol. 2025;18:105.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"938_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","volume":"25","author":"A Bot","year":"2026","unstructured":"Bot A, Scharenberg A, Friedman K, Guey L, Hofmeister R, Andorko JI, et al. In vivo chimeric antigen receptor (CAR)-T cell therapy. Nat Rev Drug Discov. 2026;25:116\u201337.","journal-title":"Nat Rev Drug Discov"},{"key":"938_CR4","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1182\/blood-2025-2323","volume":"146","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Yang Y, Liu J, He H, Hou L, Zhang M, et al. In Vivo CAR-t generation using an engineered lentiviral vector platform targeting BCMA, CD19 and CD20. Blood. 2025;146:2323\u20132323.","journal-title":"Blood"},{"key":"938_CR5","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1182\/blood-2025-2404","volume":"146","author":"X Wang","year":"2025","unstructured":"Wang X, Yang W, Wang K, Hu J, Zhou Y, Wang Y, et al. Engineering Quiescent Viral Entry Pathways for in Vivo CAR-T Generation via Binder-Fusogen Combinatorics. Blood. 2025;146:2404\u20132404.","journal-title":"Blood"},{"key":"938_CR6","doi-asserted-by":"publisher","first-page":"5896","DOI":"10.1182\/blood-2025-5896","volume":"146","author":"S Russell","year":"2025","unstructured":"Russell S, Nenavath GN, Packiriswamy N, Carey T, Gazi MY, Hawkes A, et al. Intravenously administered LV-169 delivers a functional BCMA-CAR transgene to niche-resident T cells and leads to elimination of disseminated myeloma in MHC-deficient NSG mice. Blood. 2025;146:5896\u20135896.","journal-title":"Blood"},{"key":"938_CR7","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1182\/blood-2025-4117","volume":"146","author":"R Silver","year":"2025","unstructured":"Silver R, Schindler J, Oseghali O, Reddy PN, Sun C, Madugula K, et al. In Vivo pan CAR therapy utilizing circular RNA for treatment of multiple myeloma. Blood. 2025;146:4117\u20134117.","journal-title":"Blood"},{"key":"938_CR8","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1182\/blood-2025-4106","volume":"146","author":"E Pasackow","year":"2025","unstructured":"Pasackow E, Khairallah C, Ferrell J, Graziano A, Zheng M, Tian J, et al. In Vivo generation of anti-CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases. Blood. 2025;146:4106\u20134106.","journal-title":"Blood"},{"key":"938_CR9","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.1182\/blood-2025-4131","volume":"146","author":"C Lee","year":"2025","unstructured":"Lee C, Chang A, Rimbau C, Cocker C, Bagashev A. Novel In Vivo CAR platform for autoimmune disease therapy. Blood. 2025;146:4131\u20134131.","journal-title":"Blood"},{"key":"938_CR10","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1182\/blood-2025-4318","volume":"146","author":"R Palchaudhuri","year":"2025","unstructured":"Palchaudhuri R, Monte M, Gupta M, Schiroli G, Tozzi L, Liu L, et al. In Vivo RNA delivery by targeted lipid nanoparticles enable gene editing in hematopoietic stem cells and T cells. Blood. 2025;146:4318\u20134318.","journal-title":"Blood"},{"key":"938_CR11","doi-asserted-by":"publisher","first-page":"6097","DOI":"10.1182\/blood-2025-6097","volume":"146","author":"C Cotta-Ramusino","year":"2025","unstructured":"Cotta-Ramusino C, De Iaco A, Rottman J, Rodriguez J, Li D, Venugopal K, et al. Targeted LNP delivery of an RNA gene writer In Vivo enables generation of functional CAR-T cells. Blood. 2025;146:6097\u20136097.","journal-title":"Blood"},{"key":"938_CR12","doi-asserted-by":"publisher","first-page":"LBA","DOI":"10.1182\/blood-2025-LBA-1","volume":"146","author":"S Harrison","year":"2025","unstructured":"Harrison S, Ho PJ, Lim S-L, Talam S, Pahl H, Dingar D, et al. Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti\u2013B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010. Blood. 2025;146:LBA\u20131. -1.","journal-title":"Blood"},{"key":"938_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1182\/blood-2025-103","volume":"146","author":"J Sun","year":"2025","unstructured":"Sun J, Zhu X, Xu Z, Jin J, Wang J, Tan Y, et al. Precision In Vivo CAR-T generation via CLAMP-enabled mRNA delivery: Toward scalable and translatable cell therapy. Blood. 2025;146:103\u2013103.","journal-title":"Blood"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00938-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-00938-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00938-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:05:48Z","timestamp":1779447948000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-00938-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["938"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-00938-8","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"22 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}